首页> 美国卫生研究院文献>ACS Medicinal Chemistry Letters >Structure–Activity Relationship Studies ofIsomeric 24-Diaminoquinazolines on β-Amyloid AggregationKinetics
【2h】

Structure–Activity Relationship Studies ofIsomeric 24-Diaminoquinazolines on β-Amyloid AggregationKinetics

机译:的结构-活动关系研究同构的24-二氨基喹唑啉对β-淀粉样蛋白聚集的影响动力学

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A library of isomeric 2,4-diaminoquinazoline (DAQ) derivatives were synthesized and evaluated for antiaggregation potential toward Aβ40/42. Structure–activity relationship data identified compound >3k (N4-(4-bromobenzyl)quinazoline-2,4-diamine) with a 4-bromobenzyl substituent as the most potent inhibitor (Aβ40 IC50 = 80 nM) and was almost 18-fold more potent compared to the reference agent curcumin (Aβ40 IC50 = 1.5 μM). The corresponding N2-isomer >4k (N2-(4-bromobenzyl)quinazoline-2,4-diamine) was also able to prevent Aβ aggregation (Aβ40 IC50 = 1.7 μM). However, compound >4k exhibited superior inhibition of Aβ42 aggregation (Aβ42 IC50 = 1.7 μM) compared to compound >3k (Aβ42 IC50 = 14.8 μM) and was ∼1.8-fold more potent compared to curcumin (Aβ42 IC50 = 3.1 μM). These results were supported by Aβ aggregation kinetics investigations and transmission electron microscopy studies, which demonstrate the suitability of DAQ ring system to develop antiamyloid agents as pharmacological tools to study Aβ aggregation.
机译:合成了一个2,4-二氨基喹唑啉(DAQ)异构体衍生物库,并评估了其对Aβ40/ 42的抗聚集潜力。构效关系数据确定了具有最强抑制剂的化合物> 3k (N 4 -(4-溴苄基)喹唑啉-2,4-二胺) (Aβ40IC50 = 80 nM),且效力比参考药物姜黄素(Aβ40IC50 = 1.5μM)高出近18倍。相应的N 2 -异构体> 4k (N 2 -(4-溴苄基)喹唑啉-2,4-二胺)也能够预防Aβ聚集(Aβ40IC50 = 1.7μM)。然而,与化合物> 3k (Aβ42IC50 = 14.8μM)相比,化合物> 4k 对Aβ42聚集表现出更好的抑制作用(Aβ42IC50 = 1.7μM),效力约高1.8倍与姜黄素相比(Aβ42IC50 = 3.1μM)。这些结果得到了Aβ聚集动力学研究和透射电子显微镜研究的支持,证明了DAQ环系统适合开发抗淀粉样剂作为研究Aβ聚集的药理学工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号